Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$14.72
-1.8%
$14.27
$5.68
$16.74
$921.16M-0.09749,635 shs1.23 million shs
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$31.17
+2.1%
$25.31
$19.05
$32.56
$3.73B0.722.07 million shs13.62 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.35
-0.5%
$8.00
$5.69
$13.44
$3.52B1.5719.38 million shs8.09 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$58.54
-1.7%
$51.06
$23.30
$66.06
$3.71B2.221.49 million shs1.55 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-1.80%+12.80%-0.94%+20.36%+91.52%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
+2.13%+10.81%+24.73%+27.54%+32.86%
Organon & Co. stock logo
OGN
Organon & Co.
-0.45%+0.60%+118.13%+62.55%+52.62%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.66%+0.15%+16.80%+18.91%+78.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$14.72
-1.8%
$14.27
$5.68
$16.74
$921.16M-0.09749,635 shs1.23 million shs
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$31.17
+2.1%
$25.31
$19.05
$32.56
$3.73B0.722.07 million shs13.62 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.35
-0.5%
$8.00
$5.69
$13.44
$3.52B1.5719.38 million shs8.09 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$58.54
-1.7%
$51.06
$23.30
$66.06
$3.71B2.221.49 million shs1.55 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-1.80%+12.80%-0.94%+20.36%+91.52%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
+2.13%+10.81%+24.73%+27.54%+32.86%
Organon & Co. stock logo
OGN
Organon & Co.
-0.45%+0.60%+118.13%+62.55%+52.62%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.66%+0.15%+16.80%+18.91%+78.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
2.70
Moderate Buy$29.89103.05% Upside
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
3.14
Buy$33.336.94% Upside
Organon & Co. stock logo
OGN
Organon & Co.
1.57
Reduce$11.40-14.57% Downside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$56.57-3.36% Downside

Current Analyst Ratings Breakdown

Latest CGEM, CPRX, TWST, and OGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
DowngradeOutperformMarket Perform
5/7/2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Set Price Target$32.00
5/7/2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Reiterated RatingOverweightEqual Weight
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$55.00 ➝ $60.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOutperform$50.00 ➝ $65.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UpgradeMarket PerformOutperform$70.00
5/4/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$55.00 ➝ $65.00
5/4/2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Reiterated RatingBuy$38.00
4/29/2026
Organon & Co. stock logo
OGN
Organon & Co.
Reiterated RatingOutperformNeutral$12.00 ➝ $14.00
4/28/2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Reiterated RatingBuy$38.00
4/28/2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Boost Price TargetBuy$27.00 ➝ $30.00
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$6.92 per shareN/A
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$588.99M6.47$2.99 per share10.44$7.76 per share4.02
Organon & Co. stock logo
OGN
Organon & Co.
$6.22B0.56$5.75 per share2.32$3.44 per share3.88
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M9.68N/AN/A$7.31 per share8.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$219.88M-$3.35N/AN/AN/AN/A-46.19%-43.27%N/A
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$214.33M$1.6918.4410.120.9936.39%36.47%31.85%5/11/2026 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$187M$0.9314.353.881.243.99%99.95%6.22%N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%N/A

Latest CGEM, CPRX, TWST, and OGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$0.64N/AN/AN/A$148.18 millionN/A
5/7/2026Q1 2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.8359-$0.75+$0.0859-$0.75$3.67 millionN/A
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
4/30/2026Q1 2026
Organon & Co. stock logo
OGN
Organon & Co.
$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion
3/10/2026Q4 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.80-$0.77+$0.03-$0.77$5.56 millionN/A
2/12/2026Q4 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.73$0.63-$0.10-$0.79$1.52 billion$1.51 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.60%N/A8.60%N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A

Latest CGEM, CPRX, TWST, and OGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2026
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.6%5/11/20265/11/20266/11/2026
2/12/2026
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.021.01%2/23/20262/23/20263/12/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
10.25
10.25
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
6.08
5.82
Organon & Co. stock logo
OGN
Organon & Co.
9.47
1.97
1.23
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
3.37

Institutional Ownership

CompanyInstitutional Ownership
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
7.16%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
10.40%
Organon & Co. stock logo
OGN
Organon & Co.
1.62%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3061.45 million57.05 millionOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80122.35 million109.62 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
10,000262.60 million258.35 millionNot Optionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

Twist Bioscience Q2 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$14.72 -0.27 (-1.80%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$14.73 +0.01 (+0.07%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$31.17 +0.65 (+2.13%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$31.13 -0.04 (-0.13%)
As of 07:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$13.34 -0.07 (-0.48%)
Closing price 05/7/2026 03:59 PM Eastern
Extended Trading
$13.34 -0.01 (-0.04%)
As of 07:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$58.54 -0.99 (-1.66%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$58.57 +0.03 (+0.04%)
As of 07:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.